Migdal Insurance & Financial Holdings Ltd. Sells 73,705 Shares of Eli Lilly and Company $LLY

Key Points

• Migdal Insurance & Financial Holdings reduced its Eli Lilly stake by 40.9%, selling 73,705 shares and leaving 106,335 shares valued at $114,276,000, making LLY about 1.0% of Migdal’s holdings and its 27th-largest position.
• Wall Street is broadly constructive: the stock carries a consensus rating of Moderate Buy with an average target of $1,225.33 and several firms issuing Buy/Outperform ratings with targets near $1,260–$1,300.
• Eli Lilly beat Q4 estimates (EPS $7.54; revenue +42.6%) and set FY2026 guidance of 33.5–35.0 EPS, but near-term sentiment is clouded by softer-than-expected Foundayo prescriptions and mixed GLP‑1 demand ahead of upcoming Q1 results.

Migdal Insurance & Financial Holdings Ltd. lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 40.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 106,335 shares of the company's stock after selling 73,705 shares during the period. Eli Lilly and Company makes up about 1.0% of Migdal Insurance & Financial Holdings Ltd.'s holdings, making the stock its 27th biggest position. Migdal Insurance & Financial Holdings Ltd.'s holdings in Eli Lilly and Company were worth $114,276,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. increased its holdings in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after acquiring an additional 1,141 shares during the period. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $356,000. Finally, Nebula Research & Development LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $749,000. Institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of analyst reports. Scotiabank reaffirmed an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Leerink Partners increased their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an "outperform" rating in a report on Thursday, February 5th. Bank of America increased their price target on shares of Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the stock a "buy" rating in a report on Thursday, April 2nd. Finally, The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1,225.33.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly's obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $884.88 on Friday. The company's fifty day moving average price is $958.83 and its 200-day moving average price is $983.91. The firm has a market capitalization of $836.05 billion, a price-to-earnings ratio of 38.56, a PEG ratio of 1.09 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business's revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 33.9 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.